Audited Supplier
In This Store
West Bengal Chemical Industries Limited is a 62 years old API manufacturing major of India backed by cGMP and ISO Certification. Company has two state of art manufacturing plant having around 8000 mt annual production capacity. The products cover API, Neutraceutical, Animal nutrition and the export covers the major countries across the globe. WBCIL has extensive portfolio that includes major elements with anions like ascorbate, citrate, acetate, glycinate, gluconate and many more. The recent introduction of WBCIL are Injectable Iron APIs which have been accepted globally. The company is proud recipient of eight patents in last two years. Our major products are : Ferric Citrate, Ferric Maltol, Iron Polymaltose Complex, Ferrous Bisglycinate, Ferric Ammonium Citrate, Calcium Bisglycinate ,Calcium Citrate Malate, Ferric Carboxymaltose, Iron Isomaltoside, Dimethyl Fumarate , Liposomal Iron, Liposomal Calcium, Liposomal Vitamin C,Calcium Acetate, Magnesium Pidolate,Calcium Levulinate, Calcium Lactate Gluconate & much more..
Year of Establishment: 1962
Total Assets(USD): 500,000 to 99,999,999
Total Number of Staff: 100-500
Main Competitive Advantages: Brand Name,Delivery Term,Large Product Line,Buyers' Specifications Accepted,Reputation,Quality Service
Other Competitive Advantages:
Patents and Copyrights: IMPROVED FERRIC CARBOXYMALTOSE WITH LESS SIDE-EFFECTS OBTAINED COST-EFFECTIVELY______ A COST EFFECTIVE PROCESS FOR PREPARATION OF ENCLOMIPHENE CITRATE______ IMPROVED PROCESS FOR PREPARATION OF FERRIC CARBOXYMALTOSE______ A PROCESS FOR SYNTHESIS OF FERRIC DERISOMALTOSE COMPLEX______ IMPROVED AND COST EFFECTIVE PROCESS FOR PREPARING IRON-ISOMALTOSIDE_____ SOLVENT FREE, COST EFFECTIVE PROCESS FOR PREPARATION OF FERRIC CITRATE_____ PHARMACEUTICAL ACCEPTABLE IRON (III) COORDINATION COMPLEX HAVING HIGH PHOSPHATE BINDING CAPACITY AND PREPARATION THEREOF______ PROCESS FOR PREPARATION OF SUCROFERRIC OXYHYDRATE_____
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us：
Pharma Sources Insight JANUARY 2024
